Journal: Blood
Recent advances have significantly changed the treatment landscape for relapsed and refractory follicular lymphoma.
Traditional chemotherapy, once the mainstay, is now increasingly supplemented or replaced by novel targeted therapies, immunomodulatory agents, and immunotherapeutic strategies. These approaches focus on:
- Epigenetic regulators
- B-cell receptor signaling
- The tumor microenvironment
Innovative treatments such as bispecific antibodies and CAR T-cell therapies enhance antitumor immune responses by redirecting the immune system.
Ongoing evaluation of rational combination therapies aims to extend these approaches into earlier treatment lines.
With multiple therapeutic options available, treatment decisions must be individualized based on:
- Prior therapies
- Disease biology
- Relapse characteristics
- Patient preferences
This personalized approach helps optimize outcomes in this evolving era.